What has to happen before a first human dose

A gate, not a formality

Between a promising molecule and the first person who takes it sits a defined process. It is written into federal regulation, it involves at least three separate parties, and it takes years.

Most people never see it, because by the time a medicine reaches them the process is long finished and invisible.

It becomes worth understanding in this market for the opposite reason. A great many compounds are sold to people at a stage of development that, inside the regulated system, comes before anyone is allowed to take them.

First, laboratory and animal work under a quality rule

FDA describes preclinical research as the stage that finds out whether a drug has the potential to cause serious harm, meaning toxicity. It comes in two kinds, in vitro and in vivo, which is to say laboratory systems and living animals.

This work is not left to whatever standard a laboratory chooses. FDA requires researchers to follow good laboratory practices for preclinical laboratory studies, and those regulations sit in Part 58 of Title 21.

The scope provision explains what the rule is for. It prescribes good laboratory practices for conducting nonclinical laboratory studies that support, or are intended to support, applications for research or marketing permits for FDA-regulated products.

So the animal and laboratory work has a defined purpose from the beginning. It exists to justify asking permission for the next step.

Second, an application, and a specific conclusion inside it

The permission is called an Investigational New Drug application. The regulation is blunt about when one is needed: a sponsor shall submit one if it intends to conduct a clinical investigation covered by the rule.

What the application must contain is the interesting part. It requires adequate information about pharmacological and toxicological studies of the drug, in laboratory animals or in vitro. That information is the basis on which the sponsor has concluded that it is reasonably safe to conduct the proposed clinical investigations.

That sentence carries a specific structure. The animal work is not submitted for its own sake. It is submitted as the basis for a stated conclusion about human safety, and the sponsor has to make that conclusion explicitly.

The regulation also refuses to fix the amount of evidence in advance. The kind, duration and scope of animal and other tests required varies with the duration and nature of the proposed clinical investigations. A short single-exposure study and a year-long program are not asked for the same package.

Third, a waiting period the sponsor does not control

Submitting the application does not start the trial. The regulation states that a sponsor shall not begin a clinical investigation until the investigation is subject to an application that is in effect.

Coming into effect is a separate event with its own timing. The application goes into effect thirty days after FDA receives it, unless the agency notifies the sponsor that the investigations described are subject to a clinical hold. It can also come into effect earlier, if the agency notifies the sponsor that the studies may begin.

FDA notifies the sponsor in writing of the date it received the application, so the clock has a fixed start.

The default is therefore a pause, with a route for the agency to stop the study before anyone is enrolled. Silence for thirty days is the permission.

Fourth, an independent committee

Agency clearance is not the only approval required, and the second one comes from outside the company entirely.

An institutional review board reviews the research. The regulation gives it real authority. The board shall review and have authority to approve, require modifications to secure approval, or disapprove all research activities covered by the rules.

That is a body with the power to say no to a study a sponsor has already cleared with the agency, and to demand changes before saying yes.

The board also polices what participants are told. It is required to ensure that the information given to subjects as part of informed consent meets the standard set for it.

Fifth, the consent of each person

The last permission is individual, and the rule is written as a prohibition rather than a procedure.

No investigator may involve a human being as a subject in covered research unless the investigator has obtained the legally effective informed consent of that person or their legally authorized representative.

The conditions around that consent are part of the rule. It must be sought only where there is sufficient opportunity to consider whether to take part, and in circumstances that minimize the possibility of coercion or undue influence. The information must be in language the person can understand.

The regulation also closes an obvious escape. No consent, oral or written, may include exculpatory language through which the subject waives or appears to waive legal rights.

That last clause is worth holding onto when reading any document that asks someone to accept a compound and give up the right to complain about it.

And only then, the first phase

With those permissions in place, the first human studies begin, and their purpose is narrower than most people assume.

FDA describes first-phase studies as involving 20 to 100 healthy volunteers or people with the condition, running several months, with the purpose of safety and dosage.

Effectiveness is not the question at this stage. It arrives in the next phase, in up to several hundred people with the condition, over several months to two years.

The stage that asks whether the product benefits a population comes third, in 300 to 3,000 volunteers over one to four years.

So the first legal human exposure is the beginning of a decade-shaped process, not the end of one.

What this means for a compound sold without it

Set the sequence beside how these compounds usually reach people, and the difference is not a technicality.

The sequence produces six things, in order. Quality-controlled toxicology, a written safety conclusion, agency review with a power to halt, independent committee approval, individual consent that cannot waive rights, and a monitored first study.

A vial bought online produces none of those things. A compounded preparation supplied on a prescription produces a licensed prescriber and a pharmacy, which is a real difference and a different one. Neither route generates the safety package the sequence exists to build.

That is not an argument that any particular compound is dangerous. It is a description of what is not known, and of who has not looked.

The public trace of the regulated path is the trial registry, which is where a reader can check whether a compound ever entered the sequence at all.

How to check where a compound sits

Look for registered trials of the compound, in the form and for the use being sold. A registry record shows the sequence was entered; no record shows nothing beyond the registry.

Read what the trials were for. A first-phase safety study does not support an effectiveness claim, and it was never meant to.

Notice the population. Healthy volunteers in an early study are not the people a product page is addressing.

Check the form and route, since a permission and a study attach to a specific preparation rather than to a molecule in general.

And treat the absence of any of this as information rather than as a gap to fill with a mechanism story.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 312.20 — Requirement for an IND — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
2. 21 CFR 312.23 — IND content and format — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
3. 21 CFR 312.40 — General requirements for use of an investigational new drug in a clinical investigation — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
4. 21 CFR 58.1 — Scope, good laboratory practice for nonclinical laboratory studies — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
5. 21 CFR 56.109 — IRB review of research — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
6. 21 CFR 50.20 — General requirements for informed consent — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
7. Step 2: Preclinical Research — U.S. Food and Drug Administration, January 2018
8. Step 3: Clinical Research — U.S. Food and Drug Administration, January 2018